Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic Syndrome Post Cytotoxic Therapy”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Early research (Phase 1)Active Not RecruitingNCT05146739
What this trial is testing

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Who this might be right for
Acute Myeloid Leukemia Post Cytotoxic TherapyMyelodysplastic Syndrome Post Cytotoxic TherapyMyeloid Leukemia Associated With Down Syndrome+6 more
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Looking for participantsNCT04726241
What this trial is testing

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy+5 more
PedAL BCU, LLC 960
Testing effectiveness (Phase 2)Active Not RecruitingNCT03953898
What this trial is testing

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+4 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Looking for participantsNCT05554406
What this trial is testing

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04214249
What this trial is testing

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02231853
What this trial is testing

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Who this might be right for
Chronic Lymphocytic LeukemiaCML (Chronic Myelogenous Leukemia)MDS (Myelodysplastic Syndrome)+2 more
National Heart, Lung, and Blood Institute (NHLBI) 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802161
What this trial is testing

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia With Multilineage Dysplasia+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05554419
What this trial is testing

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT05564390
What this trial is testing

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02381548
What this trial is testing

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyBlast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive+6 more
National Cancer Institute (NCI) 20
Not applicableStudy completedNCT00716911
What this trial is testing

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
City of Hope Medical Center 100
335
49
60
50
184
2,000